Use of systemic therapies for psoriasis in the COVID-19 era.
J Dermatolog Treat
; 33(2): 622-625, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-381933
ABSTRACT
BACKGROUND:
In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.OBJECTIVE:
The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic.METHODS:
Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized.RESULTS:
The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy.CONCLUSION:
Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Psoriasis
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Dermatolog Treat
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
09546634.2020.1775774
Similar
MEDLINE
...
LILACS
LIS